Proud of your work, your team and the level of science that is being done in Tucumana Florencia González Lizárraga He is grateful for the difference he received from the Argentinean biophysical association, which is its most important public institution. He was awarded the Jorge Ponce Hornos Prize after being selected among 350 scientists from across the country. "This work is my doctoral dissertation (she will be a doctor of biology), I'm the first author of the work, but we discussed these issues as a team," she explains.
The Florence investigation was conducted at the Institute of Applied Molecular and Cellular Medicine (Immca), which is dependent on UNT, Conicet and the Provincial Health Ministry, and is responsible for Rosana Chehín. This work was also counted in collaboration with the leading UBA Advanced Microscopy Center Lia Pietrasanta. Yesterday was in Florence when he spoke on the phone with LA GACETA.
The research of the new scientist is based on an antibiotic called dioxin cycline, which belongs to the tetracycline group. This antibiotic is able to interact with the protein Alpha-synuclein, which is responsible for the death of dopamine insensitive neurons (those that bind to other neurons with dopamine). These are those neurons that die in people suffering from Parkinson's disease.
But doxycycline is not suitable for long-term illnesses, such as neurodegenerative diseases, as it can lead to resistance to bacteria.
"In the second part of the work, it is necessary to find a drug called COL 3, which is also tetracycline but genetically modified in that it does not have antibiotic activity, so it will not produce resistance. It has anti-inflammatory activity and the protein alpha-synuclein is non-toxic. it has no dopant neuronal death.
"Thus Parkinson's disease stops, which means that it is not a palliative treatment, just like the current treatment methods," emphasizes Florencia.
Of course, research is still in the laboratory phase. In vitro and in vivo tests are ongoing, but there are still many opportunities for people to go through the clinical trial phase. However, it is undoubtedly a great hope.
The second mention of the Ponce Hornos Award was also Tukuman: Luciana Medinato work on Alzheimer's disease.